Research Article

Very Long Term Stability of Mixed Chimerism after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Hematologic Malignancies

Table 1

Distribution of chimerism status based on main transplant features.

FCMNC-MCGran-MCTotal value
( = 89)( = 36)( = 30)( = 155)

Gender
 Female (F)29 (0.19)16 (0.1)17 (0.11)62 (0.4)0.055
 Male (M)60 (0.39)20 (0.13)13 (0.08)93 (0.6)
Disease
 ALL16 (0.1)6 (0.04)3 (0.02)25 (0.16)0.739
 AML27 (0.17)14 (0.09)12 (0.08)53 (0.34)
 CLL3 (0.02)003 (0.02)
 CML17 (0.11)8 (0.05)7 (0.04)32 (0.21)
 Lymphoma10 (0.07)5 (0.03)1 (0.01)16 (0.1)
 MDS8 (0.05)2 (0.01)2 (0.01)12 (0.08)
 MPN2 (0.01)01 (0.01)3 (0.02)
 Myeloma6 (0.04)1 (0.01)4 (0.03)11 (0.08)
Conditioning
 Standard77 (0.5)33 (0.21)25 (0.16)135 (0.87)0.585
 Reduced12 (0.08)3 (0.02)5 (0.03)20 (0.13)
Donor type
 Identical sibling62 (0.4)29 (0.19)22 (0.14)113 (0.73)0.263
 Unrelated21 (0.14)7 (0.04)8 (0.05)36 (0.23)
 Mismatched related6 (0.04)006 (0.04)
Donor/recipient sex match
 F → F17 (0.11)10 (0.07)2 (0.01)29 (0.19)0.001
 F → M29 (0.19)5 (0.03)6 (0.04)40 (0.26)
 M → F12 (0.08)6 (0.04)15 (0.1)33 (0.21)
 M → M31 (0.2)15 (0.1)7 (0.04)53 (0.34)
T-cell depletion
 None19 (0.12)1 (0.01)020 (0.13)<0.001
 T-cell depletion without add-back48 (0.31)16 (0.1)12 (0.08)76 (0.49)
 T-cell depletion with add-back22 (0.14)19 (0.12)18 (0.12)59 (0.38)
Stem cells source
 Bone marrow26 (0.17)15 (0.1)15 (0.1)56 (0.36)0.09
 Peripheral blood63 (0.41)21 (0.14)15 (0.1)99 (0.64)
aGvHD
 Grades 0-160 (0.39)31 (0.2)25 (0.16)116 (0.75)0.045
 Grades 2–429 (0.19)5 (0.03)5 (0.03)39 (0.25)
cGvHD
 None52 (0.34)32 (0.21)24 (0.16)108 (0.7)0.009
 Limited21 (0.14)3 (0.02)3 (0.02)27 (0.17)
 Extensive16 (0.1)1 (0.01)3 (0.02)20 (0.13)
DLI
 068 (0.44)29 (0.19)20 (0.13)117 (0.76)0.406
 ≥121 (0.14)7 (0.04)10 (0.07)38 (0.24)